Upregulation of phosphorylated cofilin 1 correlates with taxol resistance in human ovarian cancer in vitro and in vivo

Oncology Reports

Volumn 29, Issue 1, 2013, Pages 58-66

  Li, Min ^a   Yin, Jie ^b   Mao, Ning ^c   Pan, Lingya ^b  

^a BEIJING HOSPITAL   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Drug resistance; Ovarian cancer; Phosphorylated cofilin 1; Proteomics; Taxol

Indexed keywords

CISPLATIN; COFILIN 1; CYCLOPHOSPHAMIDE; PACLITAXEL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MULTIPLE CYCLE TREATMENT; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, PAPILLARY; CARCINOMA, TRANSITIONAL CELL; CELL PROLIFERATION; COFILIN 1; CYSTADENOCARCINOMA, SEROUS; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PHOSPHORYLATION; PROGNOSIS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84872849872     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2078     Document Type: Article

References (32)

1. Cicchillitti L, Della Corte A, Di Michele M, Donati MB, Rotilio D and Scambia G: Characterisation of a multimeric protein complex associated with ERp57 within the nucleus in paclitaxel-sensitive and -resistant epithelial ovarian cancer cells: The involvement of specific conformational states of ß-actin. Int J Oncol 37: 445-454, 2010.
2. Bovicelli A, D'Andrilli G and Giordano A: New players in ovarian cancer. J Cell Physiol 226: 2500-2504, 2011.
3. Kurman RJ and Shih IeM: The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34: 433-443, 2010.
4. Kim A, Ueda Y, Naka T and Enomoto T: Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res 31: 14, 2012.
5. Rein DT, Volkmer A, Bauerschmitz G, et al: Combination of a MDR1-targeted replicative adenovirus and chemotherapy for the therapy of pretreated ovarian cancer. J Cancer Res Clin Oncol 138: 603-610, 2012.
6. Kavallaris M: Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 10: 194-204, 2010.
7. Umezu T, Shibata K, Kajiyama H, et al: Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin. Int J Gynecol Pathol 27: 207-212, 2008.
8. Wang Y, Chen Q, Jin S, et al: Up-regulation of P-glycoprotein is involved in the increased paclitaxel resistance in human esophageal cancer radioresistant cells. Scand J Gastroenterol 47: 802-808, 2012.
9. Yan XD, Li M, Yuan Y, Mao N and Pan LY: Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations. Oncol Rep 17: 1163-1169, 2007.
10. Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936-942, 1987.
11. Preusser M, Spiegl-Kreinecker S, Lötsch D, et al: Trabectedin has promising antineoplastic activity in high-grade meningioma. Cancer: March 5, 2012 (Epub ahead of print). doi: 10. 1002/cncr. 27460.
12. Gorg A, Obermaier C, Boguth G, et al: The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 21: 1037-1053, 2000.
13. Yan XD, Pan LY, Yuan Y, Lang JH and Mao N: Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines. J Proteome Res 6: 772-780, 2007.
14. Joubert-Caron R, Le Caer JP, Montandon F, et al: Protein analysis by mass spectrometry and sequence database searching: a proteomic approach to identify human lymphoblastoid cell line proteins. Electrophoresis 21: 2566-2575, 2000.
15. Swenerton K, Muss H and Robinson E: Salvage Chemotherapy for Refractory Disease. In: Ovarian Cancer Controversies on Management. Gershenson DM, McGuire WP (eds). Churchill Livingstone, New York, pp169-194, 1998.
16. Hsu SM, Raine L and Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29: 577-580, 1981.
17. Beamer LC, Grant ML, Espenschied CR, et al: Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. J Clin Oncol 30: 1058-1063, 2012.
18. Tanaka Y, Fujiwara K, Tanaka H, Maehata K and Kohno I: Paclitaxel inhibits expression of heat shock protein 27 in ovarian and uterine cancer cells. Int J Gynecol Cancer 14: 616-620, 2004.
19. Alli E, Yang JM, Ford JM and Hait WN: Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells. Mol Pharmacol 71: 1233-1240, 2007.
20. Song TF, Zhang ZF, Liu L, Yang T, Jiang J and Li P: Small interfering RNA-mediated silencing of heat shock protein 27 (HSP27) Increases chemosensitivity to paclitaxel by increasing production of reactive oxygen species in human ovarian cancer cells (HO8910). J Int Med Res 37: 1375-1388, 2009.
21. Balasubramani M, Nakao C, Uechi GT, et al: Characterization and detection of cellular and proteomic alterations in stable stathmin-overexpressing, taxol-resistant BT549 breast cancer cells using offgel IEF/PAGE difference gel electrophoresis. Mutat Res 722: 154-164, 2011.
22. Estornes Y, Gay F, Gevrey JC, et al: Differential involvement of destrin and cofilin-1 in the control of invasive properties of Isreco1 human colon cancer cells. Int J Cancer 121: 2162-2171, 2007.
23. Castro MA, Dal-Pizzol F, Zdanov S, et al: CFL1 expression levels as a prognostic and drug resistance marker in nonsmall cell lung cancer. Cancer 116: 3645-3655, 2010.
24. Muller CB, de Barros RL, Castro MA, et al: Validation of cofilin-1 as a biomarker in non-small cell lung cancer: application of quantitative method in a retrospective cohort. J Cancer Res Clin Oncol 137: 1309-1316, 2011.
25. Nishimura S, Tsuda H, Kataoka F, et al: Overexpression of cofilin 1 can predict progression-free survival in patients with epithelial ovarian cancer receiving standard therapy. Hum Pathol 42: 516-521, 2011.
26. Vartiainen MK, Mustonen T, Mattila PK, et al: The three mouse actin-depolymerizing factor/cofilins evolved to fulfill cell-type-specific requirements for actin dynamics. Mol Biol Cell 13: 183-194, 2002.
27. Dai YP, Bongalon S, Mutafova-Yambolieva VN and Yamboliev IA: Distinct effects of contraction agonists on the phosphorylation state of cofilin in pulmonary artery smooth muscle. Adv Pharmacol Sci 2008: 362741, 2008.
28. Klamt F, Zdanov S, Levine RL, et al: Oxidant-induced apoptosis is mediated by oxidation of the actin-regulatory protein cofilin. Nat Cell Biol 11: 1241-1246, 2009.
29. Bernstein BW and Bamburg JR: ADF/cofilin: a functional node in cell biology. Trends Cell Biol 20: 187-195, 2010.
30. Teng B, Lukasz A and Schiffer M: The ADF/cofilin-pathway and actin dynamics in podocyte injury. Int J Cell Biol 2012: 320531, 2012.
31. Ruegg J, Holsboer F, Turck C and Rein T: Cofilin 1 is revealed as an inhibitor of glucocorticoid receptor by analysis of hormone-resistant cells. Mol Cell Biol 24: 9371-9382, 2004.
32. Scott RW, Hooper S, Crighton D, et al: LIM kinases are required for invasive path generation by tumor and tumor-associated stromal cells. J Cell Biol 191: 169-185, 2010.